New Drug Zolinza
The 2009 American Society of Hematology (ASH) meeting showcased presentations on Zolinza (vorinostat), a histone deacetylase inhibitor developed by Merck Pharmaceuticals.
Zolinza alters the way a cancer cell’s DNA creates proteins. This can slow down cell proliferation, minimize mutations in DNA and control cell death. Zolinza is being investigated in combination with Revlimid and Velcade.
Zolinza alters the way a cancer cell’s DNA creates proteins. This can slow down cell proliferation, minimize mutations in DNA and control cell death. Zolinza is being investigated in combination with Revlimid and Velcade.
posted by gwg at 10:34 AM
0 Comments:
Post a Comment
<< Home